A small molecule antagonist to CX3CR1 has shown efficacy in preclinical models of breast cancer (34); however, a challenge of small molecule CX3CR1 antagonists is that they can target several related GPCRs (G Protein-coupled receptors) and are not unique to CX3CR1. This evidence concerns the gene CX3CR1 and breast cancer.